Friday, July 20, 2018 12:05:37 PM
Please read my post #13896 this AM. A VERY STRONG dissenting opinion!
No need for any fear. I would also recommend the article by Zach Hartman, PhD. Here's the relevant exerpt:
"it should be emphasized that (Novartis's) eltrombopag is not likely to be a strong competitor (to Pluristem), since there is a lot more that needs to be done to repair the damage done by radiation."
I hope your fears have been allayed!
if not read my additional comments:
I see Novartis' interest as a POSITIVE! It shows that the target indications (multiple) represent a huge value. Pluristem will be there first and with a better product!
If you're still afraid do some research on PLX-R18 and the realization that a live cell, responding to the distress signals coming from the very cells that are in trouble, will be a more effective treatment option, your fears will subside. In fact I would say that PLX-R18 is a very good treatment for fears about BIG Novartis.
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM